TipRanks
Medline (MDLN)
NASDAQ:MDLN
US Market
MDLN
Medline
RESEARCH TOOLSreports
Want to see MDLN full AI Analyst Report?

Medline (MDLN) Stock Forecast & Price Target

313 Followers
See the Price Targets and Ratings of:

MDLN Analyst Ratings

Strong Buy
20Ratings
Strong Buy
18 Buy
2 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Medline
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDLN Stock 12 Month Forecast

Average Price Target

$44.76
▲(23.32% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Medline in the last 3 months. The average price target is $44.76 with a high forecast of $55.00 and a low forecast of $34.00. The average price target represents a 23.32% change from the last price of $36.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","56":"$56","38.75":"$38.8","44.5":"$44.5","50.25":"$50.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.76470588235294,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,38.75,44.5,50.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.94,36.48307692307692,38.026153846153846,39.56923076923077,41.11230769230769,42.65538461538461,44.19846153846154,45.74153846153846,47.284615384615385,48.8276923076923,50.37076923076923,51.91384615384615,53.456923076923076,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.94,35.695746606334836,36.45149321266968,37.20723981900452,37.962986425339366,38.718733031674205,39.47447963800905,40.23022624434389,40.985972850678735,41.74171945701357,42.49746606334842,43.25321266968326,44.0089592760181,{"y":44.76470588235294,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.94,34.86769230769231,34.79538461538461,34.723076923076924,34.65076923076923,34.57846153846154,34.50615384615384,34.433846153846154,34.36153846153846,34.28923076923077,34.216923076923074,34.144615384615385,34.07230769230769,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.73,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.28,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.11,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.94,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$55.00Average Price Target$44.76Lowest Price Target$34.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MDLN
Glen Santangelo
Barclays
Barclays
$45→$43
Buy
18.46%
Upside
Reiterated
10/09/26
Leerink Partners Analyst forecast on MDLN
Michael Cherny
Leerink Partners
Leerink Partners
$43
Buy
18.46%
Upside
Reiterated
10/07/26
Analysts Conflicted on These NA Names: Venture Global, Inc. Class A (NYSE: VG), ServiceTitan, Inc. Class A (NASDAQ: TTAN) and Medline (NASDAQ: MDLN)
RBC Capital Analyst forecast on MDLN
Ryan Halsted
RBC Capital
RBC Capital
$46
Buy
26.72%
Upside
Reiterated
10/06/26
RBC Capital Sticks to Their Buy Rating for Medline (MDLN)
UBS Analyst forecast on MDLN
Kevin Caliendo
UBS
UBS
$45→$43
Buy
18.46%
Upside
Assigned
09/25/26
Medline price target lowered to $43 from $45 at UBSMedline price target lowered to $43 from $45 at UBS
William Blair Analyst forecast on MDLN
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
09/23/26
Analysts Offer Insights on NA Companies: Micron (NASDAQ: MU) and Medline (NASDAQ: MDLN)
Truist Financial Analyst forecast on MDLN
Jailendra Singh
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on NA Companies: Millrose Properties Inc Class A (NYSE: MRP) and Medline (NASDAQ: MDLN)
BTIG Analyst forecast on MDLN
David Larsen
BTIG
BTIG
$55
Buy
51.52%
Upside
Reiterated
08/27/26
Analysts Offer Insights on NA Companies: Veeva Systems (NYSE: VEEV), Blue Owl Technology Finance Corp. (NYSE: OTF) and Medline (NASDAQ: MDLN)
Tigress Financial Analyst forecast on MDLN
Ivan Feinseth
Tigress Financial
Tigress Financial
$62→$55
Buy
51.52%
Upside
Reiterated
08/14/26
Medline price target lowered to $55 from $62 at Tigress FinancialMedline price target lowered to $55 from $62 at Tigress Financial
J.P. Morgan Analyst forecast on MDLN
Lisa Gill
J.P. Morgan
J.P. Morgan
$53→$46
Buy
26.72%
Upside
Reiterated
08/12/26
J.P. Morgan Sticks to Its Buy Rating for Medline (MDLN)
Wells Fargo Analyst forecast on MDLN
Stephen Baxter
Wells Fargo
Wells Fargo
$45→$34
Hold
-6.34%
Downside
Assigned
08/11/26
Wells Fargo Issues a Hold Rating on Medline (MDLN)
TD Cowen Analyst forecast on MDLN
Charles Rhyee
TD Cowen
TD Cowen
$53→$45
Buy
23.97%
Upside
Assigned
08/10/26
Charles Rhyee Reaffirms Buy on Medline as Price Target Cut to $45, Backed by Strong Cash Flow and 2027 Growth Outlook
Bank of America Securities Analyst forecast on MDLN
Andrew Obin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on NA Companies: Circle Internet Group, Inc. Class A (NYSE: CRCL), Carlsmed, Inc. (NASDAQ: CARL) and Medline (NASDAQ: MDLN)
Morgan Stanley Analyst forecast on MDLN
Erin Wright
Morgan Stanley
Morgan Stanley
$52→$48
Buy
32.23%
Upside
Reiterated
08/06/26
Analysts Conflicted on These NA Names: Medline (NASDAQ: MDLN), Ardent Health Partners, Inc. (NYSE: ARDT) and Figma, Inc. Class A (NYSE: FIG)
Robert W. Baird Analyst forecast on MDLN
Eric Coldwell
Robert W. Baird
Robert W. Baird
$45→$42
Buy
15.70%
Upside
Reiterated
08/06/26
Medline price target lowered to $42 from $45 at BairdqMedline price target lowered to $42 from $45 at Bairdq
Deutsche Bank Analyst forecast on MDLN
Pito Chickering
Deutsche Bank
Deutsche Bank
$42→$37
Hold
1.93%
Upside
Assigned
08/06/26
Medline price target lowered to $37 from $42 at Deutsche BankMedline price target lowered to $37 from $42 at Deutsche Bank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MDLN
Glen Santangelo
Barclays
Barclays
$45→$43
Buy
18.46%
Upside
Reiterated
10/09/26
Leerink Partners Analyst forecast on MDLN
Michael Cherny
Leerink Partners
Leerink Partners
$43
Buy
18.46%
Upside
Reiterated
10/07/26
Analysts Conflicted on These NA Names: Venture Global, Inc. Class A (NYSE: VG), ServiceTitan, Inc. Class A (NASDAQ: TTAN) and Medline (NASDAQ: MDLN)
RBC Capital Analyst forecast on MDLN
Ryan Halsted
RBC Capital
RBC Capital
$46
Buy
26.72%
Upside
Reiterated
10/06/26
RBC Capital Sticks to Their Buy Rating for Medline (MDLN)
UBS Analyst forecast on MDLN
Kevin Caliendo
UBS
UBS
$45→$43
Buy
18.46%
Upside
Assigned
09/25/26
Medline price target lowered to $43 from $45 at UBSMedline price target lowered to $43 from $45 at UBS
William Blair Analyst forecast on MDLN
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
09/23/26
Analysts Offer Insights on NA Companies: Micron (NASDAQ: MU) and Medline (NASDAQ: MDLN)
Truist Financial Analyst forecast on MDLN
Jailendra Singh
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on NA Companies: Millrose Properties Inc Class A (NYSE: MRP) and Medline (NASDAQ: MDLN)
BTIG Analyst forecast on MDLN
David Larsen
BTIG
BTIG
$55
Buy
51.52%
Upside
Reiterated
08/27/26
Analysts Offer Insights on NA Companies: Veeva Systems (NYSE: VEEV), Blue Owl Technology Finance Corp. (NYSE: OTF) and Medline (NASDAQ: MDLN)
Tigress Financial Analyst forecast on MDLN
Ivan Feinseth
Tigress Financial
Tigress Financial
$62→$55
Buy
51.52%
Upside
Reiterated
08/14/26
Medline price target lowered to $55 from $62 at Tigress FinancialMedline price target lowered to $55 from $62 at Tigress Financial
J.P. Morgan Analyst forecast on MDLN
Lisa Gill
J.P. Morgan
J.P. Morgan
$53→$46
Buy
26.72%
Upside
Reiterated
08/12/26
J.P. Morgan Sticks to Its Buy Rating for Medline (MDLN)
Wells Fargo Analyst forecast on MDLN
Stephen Baxter
Wells Fargo
Wells Fargo
$45→$34
Hold
-6.34%
Downside
Assigned
08/11/26
Wells Fargo Issues a Hold Rating on Medline (MDLN)
TD Cowen Analyst forecast on MDLN
Charles Rhyee
TD Cowen
TD Cowen
$53→$45
Buy
23.97%
Upside
Assigned
08/10/26
Charles Rhyee Reaffirms Buy on Medline as Price Target Cut to $45, Backed by Strong Cash Flow and 2027 Growth Outlook
Bank of America Securities Analyst forecast on MDLN
Andrew Obin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on NA Companies: Circle Internet Group, Inc. Class A (NYSE: CRCL), Carlsmed, Inc. (NASDAQ: CARL) and Medline (NASDAQ: MDLN)
Morgan Stanley Analyst forecast on MDLN
Erin Wright
Morgan Stanley
Morgan Stanley
$52→$48
Buy
32.23%
Upside
Reiterated
08/06/26
Analysts Conflicted on These NA Names: Medline (NASDAQ: MDLN), Ardent Health Partners, Inc. (NYSE: ARDT) and Figma, Inc. Class A (NYSE: FIG)
Robert W. Baird Analyst forecast on MDLN
Eric Coldwell
Robert W. Baird
Robert W. Baird
$45→$42
Buy
15.70%
Upside
Reiterated
08/06/26
Medline price target lowered to $42 from $45 at BairdqMedline price target lowered to $42 from $45 at Bairdq
Deutsche Bank Analyst forecast on MDLN
Pito Chickering
Deutsche Bank
Deutsche Bank
$42→$37
Hold
1.93%
Upside
Assigned
08/06/26
Medline price target lowered to $37 from $42 at Deutsche BankMedline price target lowered to $37 from $42 at Deutsche Bank
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medline

3 Months
Eric ColdwellRobert W. Baird
Success Rate
3/4 ratings generated profit
75%
Average Return
-1.03%
Copying Eric Coldwell's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of -1.03% per trade.
1 Year
Eric ColdwellRobert W. Baird
Success Rate
2/4 ratings generated profit
50%
Average Return
-5.85%
Copying Eric Coldwell's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.85% per trade.
2 Years
Eric ColdwellRobert W. Baird
Success Rate
2/4 ratings generated profit
50%
Average Return
-5.85%
Copying Eric Coldwell's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -5.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDLN Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
2
2
4
3
3
Buy
23
26
26
25
23
Hold
2
2
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
30
32
30
28
In the current month, MDLN has received 26 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MDLN average Analyst price target in the past 3 months is 44.76.
Each month's total comprises the sum of three months' worth of ratings.

MDLN Financial Forecast

MDLN Earnings Forecast

Next quarter’s earnings estimate for MDLN is $0.34 with a range of $0.28 to $0.41. The previous quarter’s EPS was $0.50. MDLN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year MDLN has Performed in-line its overall industry.
Next quarter’s earnings estimate for MDLN is $0.34 with a range of $0.28 to $0.41. The previous quarter’s EPS was $0.50. MDLN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year MDLN has Performed in-line its overall industry.

MDLN Sales Forecast

Next quarter’s sales forecast for MDLN is $7.72B with a range of $7.66B to $7.89B. The previous quarter’s sales results were $7.68B. MDLN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year MDLN has Performed in-line its overall industry.
Next quarter’s sales forecast for MDLN is $7.72B with a range of $7.66B to $7.89B. The previous quarter’s sales results were $7.68B. MDLN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year MDLN has Performed in-line its overall industry.

MDLN Stock Forecast FAQ

What is MDLN’s average 12-month price target, according to analysts?
Based on analyst ratings, Medline’s 12-month average price target is 44.76.
    What is MDLN’s upside potential, based on the analysts’ average price target?
    Medline has 23.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MDLN a Buy, Sell or Hold?
          Medline has a consensus rating of Strong Buy which is based on 18 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Medline’s price target?
            The average price target for Medline is 44.76. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $55.00 ,the lowest forecast is $34.00. The average price target represents 23.32% Increase from the current price of $36.3.
              What do analysts say about Medline?
              Medline’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of MDLN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.